Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LP-08 · 1 trial · 1 indication
The number/severity of adverse events throughout the study
| Arm | Type | Description |
|---|---|---|
| LP-08 80mg | ACTIVE_COMPARATOR | 4 weekly intravesical administration of LP-08 80mg |
| LP-08 20mg | ACTIVE_COMPARATOR | 4 weekly intravesical administration of LP-08 20mg |
| Normal Saline | PLACEBO_COMPARATOR | Four weekly normal saline intravesical administration |
| Name | Type | Description |
|---|---|---|
| LP-08 80mg | DRUG | Intravesical instillation of 80mg LP08 |
| Normal saline | DRUG | Intravesical instillation of normal saline |
| LP-08 20mg | DRUG | Intravesical instillation of 20mg LP08 |
Inclusion Criteria: A patient is deemed suitable for inclusion in the study if the patient meets the following criteria: 1. Male or female at least 18 years of age 2. IC/BPS diagnosed by a health care provider based the following criteria: Complaint of suprapubic pain related to bladder fillin...
LP-08 is an investigational small molecule being developed for the treatment of interstitial cystitis, also known as painful bladder syndrome. It is administered intravesically, meaning directly into the bladder. The drug is currently in clinical development and has not been approved by the FDA.
LP-08 is being developed by Lipella Pharmaceuticals Inc., a company traded on the stock exchange under the ticker symbol LIPO. The company is conducting clinical research to evaluate the safety and efficacy of LP-08 for interstitial cystitis.
LP-08 is in Phase 2 clinical development. A Phase 2 clinical trial has been completed to evaluate the drug in patients with interstitial cystitis. The drug is still investigational and has not received regulatory approval.
LP-08 has been studied in one completed Phase 2 clinical trial with the identifier NCT01393223. This trial, titled 'Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome,' enrolled 21 participants in the United States. The trial was randomized, double-blind, and placebo-controlled.
LP-08 and LP08 refer to the same investigational drug. The clinical trial NCT01393223 uses the name LP08 in its title, while the drug is also referred to as LP-08. Both names denote the same small molecule being developed for interstitial cystitis.